The reports of counterfeiting seem to be on the increase, with no let down in sight. And while there are a number of effective technologies that address diversion and counterfeiting, their adoption rate appears to be very slow. Even FDA recognized this and convened another workshop on RFID and anti-counterfeiting in February to address the lack of appreciable progress.

Why are drug manufacturers willing to invest so much in developing products, yet hesitating to invest in protecting themselves and ensuring patient safety? Aren’t these companies leaving themselves open to significant liability by not adopting any anti-counterfeit measures that would provide layers for patient safety?

If we were to examine the drivers for anti-counterfeiting, we would find significant business value through the goals of patient safety, brand protection, differentiation, and supplychain efficiencies.

Reprinted with Permission from www.cortegra.com